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of ischemia. Elevated levels powerfully predict adverse events in
patients with coronary syndromes (7). Intravenous BNP (nesirit-
ide) is of proven benefit in managing cardiac patients.
Raised PAPP-A and BNP levels may be part of endogenous
compensatory pathways aimed at tissue salvage and repair. We
believe they strongly predict adverse outcomes because they are
sensitive signals of damage, without necessarily causing it.
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REPLY
We thank Dr. Conti and colleagues for their interesting contri-
bution regarding our recent study on the predictive value of
pregnancy-associated plasma protein-A (PAPP-A) in patients
with acute coronary syndromes (ACS) (1). As stated in the
discussion section of our report, the exact role of PAPP-A in the
pathophysiology in ACS still remains illusive. In this context, we
could only speculate about the putative role of the metalloprotein-
ase (MMP) PAPP-A in the setting of atherosclerotic plaque
destabilization, which may lead to clinical manifestation as an
ACS. We completely agree with Dr. Conti and colleagues that no
data are currently available directly demonstrating that PAPP-A
per se leads to degradation of extracellular matrix. However,
because matrix degradation has been shown for other MMPs, it is
quite reasonable to assume that PAPP-A may also act at least in
part through a similar mechanism.
Of note, release and subsequent activation of insulin-like
growth factor-1 (IGF-1), a potential protective factor in the
cardiovascular system, through PAPP-A activation may indeed
represent an alternative mechanism as suggested by Conti et al.
(2). Although this potential mechanism proposed by Dr. Conti
and co-workers is similarly reasonable and appealing, there is
also no definitive evidence that this is the most relevant
mechanism of action of PAPP-A in the setting of an ACS.
Unfortunately, we can neither support nor disprove the re-
searchers’ hypothesis as we did not have a chance to measure
IGF-1 levels in our study populations. Actually, it would not
seem to be appropriate to draw mechanistic conclusions from
this kind of clinical study. Circulating levels of biomarkers such
as PAPP-A only represent the integral of PAPP-A generation as
well as degradation in patients with ACS, but these studies alone
cannot provide any hint on the source and the mode of action of
PAPP-A in unstable atherosclerotic plaques, respectively. Thus,
one should be very cautious in drawing any definite mechanistic
conclusions from the levels of circulating biomarkers in any
disease. Apparently, further experimental studies are truly needed
to prove the exact role and mechanism of PAPP-A in atheroscle-
rosis and its complications.
In summary, we aimed in our study to place the biomarker
PAPP-A into the context of inflammation and matrix degradation
as this view is supported by the current literature (3–5). Indepen-
dent of the actual mechanism by which PAPP-A may contribute
to plaque destabilization and/or plaque healing, however, PAPP-A
remains an independent and powerful predictor for adverse events
in patients with ACS and, thus, deserves further investigation
regarding its clinical utility as a diagnostic biomarker.
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Black Pearl in the LIFE Study: Angiotensin-II
Receptor Blockade on Atrial Fibrillation for
Future Personalized Medicine
The LIFE study by Wachtell et al. (1) presented evidence
indicating that losartan significantly reduces new-onset atrial
fibrillation (AF) in comparison to atenolol-based antihypertensive
treatment and thereby supports recent studies in this field (2,3).
Conversely, the LIFE study revealed that new-onset AF was more
frequent in losartan-treated blacks (1.9%) than in atenolol-treated
blacks (0.8%). In addition, van der Hooft’s report explained that
losartan was one of several drugs that possibly could induce AF (4).
Moreover, the occurrence of AF tended to be more frequent in the
valsartan group (2.4%) than in the amlodipine group (2.0%) in the
VALUE trial (5).
These results surprised and persuaded us to move forward with
our own study of AF. We hypothesize that certain types of AF are
associated with reduced activation of the renin-angiotensin system
(RAS), especially in patients with a small left ventricular cavity
(SLVC) due to hypertrophy (6–8). The mechanism of the
development of AF in these patients remains unclear. However, we
do know that the RAS regulates sodium balance, intravascular
volume, and blood pressure. As a result, inhibiting the RAS in
patients with an SLVC may induce hypotension, increased heart
rate, and hypercontraction due to systolic emptying, which may be
related to the autonomic effects on pulmonary venous foci and AF
(6–8).
Blacks were reported to have more severe left ventricular (LV)
hypertrophy than whites with similar levels of hypertension (9). In
addition, multivariable-adjusted LV internal dimensions are
smaller in blacks than in whites (9), suggesting that SLVC may be
more common in black than white hypertensive patients. Taking
these data into consideration, our speculation may be compatible
with a part of the LIFE or VALUE study results.
Because of the small percentage (10%) of participants who
underwent echocardiographic assessments in the LIFE study (1),
the true severity of LV hypertrophy and the LV cavity size are
unclear. Commonly used electrocardiographic criteria for detection
of LV hypertrophy were reported to have poor sensitivity among
both black and white hypertensive patients (10). We suggest that
future studies should analyze whether or not the incidence of AF
differs in the presence of an SLVC owing to hypertrophy between
drug groups.
In conclusion, although an angiotensin-converting enzyme
inhibitor or an angiotensin receptor blocker may prevent most
types of AF, they also may in fact provoke the development of
certain types of AF in SLVC patients. Our speculation needs to be
confirmed among hypertensive patients with an SLVC due to
hypertrophy in a large-scale randomized clinical trial. These
analyses may show a more optimal choice for initial pharmaco-
therapy of hypertension for future personalized medicine.
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We would like to thank Dr. Ogimoto and colleagues for their interest
in our study showing that losartan reduced the incidence of new-onset
atrial fibrillation (AF) by 33% compared to atenolol (1). Dr. Ogimoto
and colleagues note that the incidence of new-onset AF is numerically
higher among black patients treated with losartan compared to those
treated with atenolol. However, the data we presented do not provide
statistical support for a difference in the incidence of new-onset
strokes between blacks on losartan-based compared to atenolol-based
treatment (n 5 [ 1.9%] vs. 2 [0.8%], HR [hazard ratio] 2.5 [95%
confidence interval 0.48–12.8], p  0.279). Furthermore, there was
no association of black versus white ethnicity and new-onset AF (p
0.11). Thus, the LIFE data do not document ethnic differences in
either new-onset AF or treatment effects thereon.
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